Lead sponsor
Alnylam Pharmaceuticals
3 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
3
Trials led
3
Ongoing
168
Total enrollment
20
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
2
Phase 2
1
Trials by status
Not yet recruiting
1
Recruiting
2
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOADMMSE ≥20Ph 1Recruiting60
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)Amyloid biomarker required (PET)Ph 2Not yet recruiting58
A Study to Evaluate ALN-5288 in Patients With Alzheimer's DiseaseAlzheimer's diseasePh 1Recruiting50